366 related articles for article (PubMed ID: 10406467)
1. Molecular modeling of human P450c17 (17alpha-hydroxylase/17,20-lyase): insights into reaction mechanisms and effects of mutations.
Auchus RJ; Miller WL
Mol Endocrinol; 1999 Jul; 13(7):1169-82. PubMed ID: 10406467
[TBL] [Abstract][Full Text] [Related]
2. Modeling and mutagenesis of the active site of human P450c17.
Lin D; Zhang LH; Chiao E; Miller WL
Mol Endocrinol; 1994 Mar; 8(3):392-402. PubMed ID: 8015556
[TBL] [Abstract][Full Text] [Related]
3. Modulation of 17alpha-hydroxylase/17,20-lyase activity of guinea pig cytochrome P450c17 by site-directed mutagenesis.
Beaudoin C; Lavallée B; Tremblay Y; Hum DW; Breton R; de Launoit Y; Bélanger A
DNA Cell Biol; 1998 Aug; 17(8):707-15. PubMed ID: 9726253
[TBL] [Abstract][Full Text] [Related]
4. Biochemical differences between rat and human cytochrome P450c17 support the different steroidogenic needs of these two species.
Brock BJ; Waterman MR
Biochemistry; 1999 Feb; 38(5):1598-606. PubMed ID: 9931027
[TBL] [Abstract][Full Text] [Related]
5. The regulation of 17,20 lyase activity.
Miller WL; Auchus RJ; Geller DH
Steroids; 1997 Jan; 62(1):133-42. PubMed ID: 9029728
[TBL] [Abstract][Full Text] [Related]
6. The molecular basis of isolated 17,20 lyase deficiency.
Miller WL; Geller DH; Auchus RJ
Endocr Res; 1998; 24(3-4):817-25. PubMed ID: 9888582
[TBL] [Abstract][Full Text] [Related]
7. Pitfalls in characterizing P450c17 mutations associated with isolated 17,20-lyase deficiency.
Gupta MK; Geller DH; Auchus RJ
J Clin Endocrinol Metab; 2001 Sep; 86(9):4416-23. PubMed ID: 11549685
[TBL] [Abstract][Full Text] [Related]
8. Steroid 17 alpha-hydroxylase and 17,20-lyase activities of P450c17: contributions of serine106 and P450 reductase.
Lin D; Black SM; Nagahama Y; Miller WL
Endocrinology; 1993 Jun; 132(6):2498-506. PubMed ID: 8504753
[TBL] [Abstract][Full Text] [Related]
9. Novel mutation of the CYP17 gene in two unrelated patients with combined 17alpha-hydroxylase/17,20-lyase deficiency: demonstration of absent enzyme activity by expressing the mutant CYP17 gene and by three-dimensional modeling.
Patocs A; Liko I; Varga I; Gergics P; Boros A; Futo L; Kun I; Bertalan R; Toth S; Pazmany T; Toth M; Szücs N; Horanyi J; Glaz E; Racz K
J Steroid Biochem Mol Biol; 2005 Nov; 97(3):257-65. PubMed ID: 16176874
[TBL] [Abstract][Full Text] [Related]
10. P450c17 mutations R347H and R358Q selectively disrupt 17,20-lyase activity by disrupting interactions with P450 oxidoreductase and cytochrome b5.
Geller DH; Auchus RJ; Miller WL
Mol Endocrinol; 1999 Jan; 13(1):167-75. PubMed ID: 9892022
[TBL] [Abstract][Full Text] [Related]
11. Molecular dynamics of substrate complexes with hamster cytochrome P450c17 (CYP17): mechanistic approach to understanding substrate binding and activities.
Mathieu AP; LeHoux JG; Auchus RJ
Biochim Biophys Acta; 2003 Feb; 1619(3):291-300. PubMed ID: 12573489
[TBL] [Abstract][Full Text] [Related]
12. Homology modelling of the enzyme P450 17 alpha-hydroxylase/17,20-lyase--a target for prostate cancer chemotherapy--from the crystal structure of P450BM-3.
Burke DF; Laughton CA; Neidle S
Anticancer Drug Des; 1997 Mar; 12(2):113-23. PubMed ID: 9113066
[TBL] [Abstract][Full Text] [Related]
13. CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding.
Sherbet DP; Tiosano D; Kwist KM; Hochberg Z; Auchus RJ
J Biol Chem; 2003 Dec; 278(49):48563-9. PubMed ID: 14504283
[TBL] [Abstract][Full Text] [Related]
14. NADPH-flavodoxin reductase and flavodoxin from Escherichia coli: characteristics as a soluble microsomal P450 reductase.
Jenkins CM; Waterman MR
Biochemistry; 1998 Apr; 37(17):6106-13. PubMed ID: 9558349
[TBL] [Abstract][Full Text] [Related]
15. Molecular evolution of adrenarche: structural and functional analysis of p450c17 from four primate species.
Arlt W; Martens JW; Song M; Wang JT; Auchus RJ; Miller WL
Endocrinology; 2002 Dec; 143(12):4665-72. PubMed ID: 12446594
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the hamster and human adrenal P450c17 (17 alpha-hydroxylase/17,20-lyase) using site-directed mutagenesis and molecular modeling.
Mathieu AP; Auchus RJ; LeHoux JG
J Steroid Biochem Mol Biol; 2002 Jan; 80(1):99-107. PubMed ID: 11867269
[TBL] [Abstract][Full Text] [Related]
17. Differential inhibition of 17alpha-hydroxylase and 17,20-lyase activities by three novel missense CYP17 mutations identified in patients with P450c17 deficiency.
Van Den Akker EL; Koper JW; Boehmer AL; Themmen AP; Verhoef-Post M; Timmerman MA; Otten BJ; Drop SL; De Jong FH
J Clin Endocrinol Metab; 2002 Dec; 87(12):5714-21. PubMed ID: 12466376
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the 17 alpha-hydroxylase/C17,20-lyase activities of porcine, guinea pig and bovine P450c17 using purified recombinant fusion proteins containing P450c17 linked to NADPH-P450 reductase.
Shet MS; Fisher CW; Tremblay Y; Belanger A; Conley AJ; Mason JI; Estabrook RW
Drug Metab Rev; 2007; 39(2-3):289-307. PubMed ID: 17786622
[TBL] [Abstract][Full Text] [Related]
19. A single amino acid residue, Ala 105, confers 16alpha-hydroxylase activity to human cytochrome P450 17alpha-hydroxylase/17,20 lyase.
Swart AC; Storbeck KH; Swart P
J Steroid Biochem Mol Biol; 2010 Apr; 119(3-5):112-20. PubMed ID: 20043997
[TBL] [Abstract][Full Text] [Related]
20. Active site proton delivery and the lyase activity of human CYP17A1.
Khatri Y; Gregory MC; Grinkova YV; Denisov IG; Sligar SG
Biochem Biophys Res Commun; 2014 Jan; 443(1):179-84. PubMed ID: 24299954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
